Clinuvel says photoprotective drug positive in Phase III trial for rare light disease
This article was originally published in Scrip
Executive Summary
A Phase III trial of Clinuvel's lead photoprotective drug Scenesse (afamelanotide) has shown that the drug has the ability to reduce painful phototoxic reactions experienced by patients with a rare genetic disorder called erythropoietic protoporphyria (EPP), according to the Australian-based company.